Growing Use of Liposomal Doxorubicin in Effectively Treating Cancer

The global Liposomal Doxorubicin Market size is projected to surpass USD 1.9 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.2% during the forecast period, 2022–2030. This growth is attributed to the increasing prevalence of cancer and rising awareness about the benefits of liposomal doxorubicin over traditional doxorubicin use across the world.

What Does Liposomal Mean?

According to cancer.gov, liposomal is a drug preparation that encapsulates an active drug payload inside tiny and fat-like particles. Liposomal form drugs are beneficial for the body to effectively absorb the drug and enable it to reach the target areas such as tumors or disease-infected cells within the body. Additionally, liposomes have fewer side effects on the individual’s body, and they work much better than the other traditional drug forms.

Doxorubicin Liposomes

Doxorubicin Liposomes is an anti-cancer medicine used for chemotherapy treatment. The trade name used for doxorubicin liposomes by healthcare professionals is Doxil. The drug is contained in closed small lipid spheres called pegylated liposomes. The spheres are able to keep the doxorubicin in blood flow for a longer duration which allows more of the drug to reach cancerous cells and stop them from further growing.

Doxorubicin (liposomal) cannot be given through tablets. The drug is inserted into the cancer patient’s body by the injection method through a vein. Liposomal doxorubicin drug is commonly used for treating ovarian cancer and Kaposi sarcoma (HIV patients).

Get a Free Sample Report @
https://growthmarketreports.com/request-sample/2492

Comparison: Liposomal Doxorubicin vs Doxorubicin:

Doxorubicin is used as a chemotherapy drug, which is identified as anthracycline. The drug is mostly used in treating superficial bladder cancer. The drug works by blocking topoisomerase 2 enzymes, which cancer cells need for dividing and growing in the body. On the other hand, liposomal doxorubicin formulation consists of doxorubicin which flows through the bloodstream for a longer duration in order to take most of the drug to the cancer-affected cells.

Doxorubicin retention time in cells is shorter and has comparatively more side effects than Doxil. Since lipodox stays in blood circulation for a longer duration and has a lower clearance rate than doxorubicin it could help in improving cancer therapy and lessen the normal tissue toxicity of doxorubicin.

Doxil Success Rate:

Several studies have proved that the Doxil success rate is higher than the normal doxorubicin use in chemotherapy. Doxil is slowly released within the patient’s body over time and it stays longer in the bloodstream owing to which treatments are needed less often than with the traditional use of doxorubicin.

Doxil Side Effects:

• Before using any medicine, its side effects need to be weighed against the benefits it will provide to the patient’s body. Side effects and their intensity depends on the proportions of the drug given to the patient, which means higher doses could cause severe side effects on the patient’s health.
• Doxil is categorized as an irritant. The chemicals can cause inflation to the vein through which the drug is given, and if the drug escapes the vein it can result in tissue damage. The healthcare professional who injects the drug needs to be trained carefully under expert observation.
• Symptoms such as a temporary decrease of white and red blood cells, mouth sores, rashes, redness, swelling, pain, or peeling of the skin on palms & feet are commonly observed side effects due to the higher dose of Doxil.

To Know More @
https://growthmarketreports.com/report/liposomal-doxorubicin-market-global-industry-analysis

Key Insights: 

• The demand for liposomal doxorubicin is rising owing to the growing awareness about newer and more effective cancer treatments than traditional treatments.
• The rising number of cancer cases across the world is expected to drive the demand for sophisticated cancer treatment medicines such as Doxil, which positively impacts cancer patients for a longer duration and also reduces the number of chemotherapy sessions.
• Compared to other medicines doxorubicin liposomes have fewer side effects involved, owing to which its demand is expected to keep on growing in the coming years.
• The largest demand for liposomal doxorubicin comes from North America owing to the rising cases of sarcomas & ovarian, breast, and liver cancers in the region.
• Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Pfizer Inc; Sun Pharmaceutical Industries Ltd.; Cadila Pharmaceuticals; SRS Pharmaceuticals Pvt. Ltd.; and Cipla, Inc. are some of the leading providers of Doxil across the globe.